Dilation Clinical Trial
Official title:
Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients
To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: - Receiving pupillary dilation in both eyes as part of the participant's standard of care. Exclusion Criteria: - Pupillary or anterior segment abnormality - Participants with pre-existing health conditions that would prevent pupillary dilation. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent change in Spherical equivalent | Cycloplegia is the paralysis of the ciliary muscle of the eye resulting in dilatation of the pupil and paralysis of accommodation.
Cycloplegia is defined as the "change score." Change scores were calculated by subtracting the spherical equivalent value after dilation from the value before dilation for each eye. |
Before dilation and 30 minutes after dilation | |
Primary | Percent Change in maximum pupil diameter | The pupil is the opening in the center of the iris (the structure that gives particpant's eyes their color). The diameter is a straight line passing from side to side through the center of the pupil, which is shaped like a circle. | Before dilation and 30 minutes after dilation | |
Primary | Percent Change in pupil constriction percentage | Pupillary constriction percentage was calculated by the pupillometer in response to a 180-micro watt flash: (maximum - minimum) / maximum | Before and 30 minutes after dilation | |
Secondary | Percent Change in Intraocular Pressure | Intraocular pressure is the pressure, or force, inside of the participants eyes. Specifically, it's a measurement of the fluid pressure in the participant's aqueous humor. | Before and 30 minutes After Dilation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05134974 -
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
|
Phase 3 | |
Completed |
NCT04620213 -
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
|
Phase 3 | |
Completed |
NCT05274321 -
Efficacy of the Nanodropper Device on Pupillary Dilation
|
N/A | |
Completed |
NCT05223478 -
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04024891 -
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
|
Phase 2 |